422 related articles for article (PubMed ID: 29623679)
21. Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases.
Brites L; Madeira N; Rodrigues J; Marona J; Martins N; Águeda A; Freitas R; Neto A; Capela S; Sequeira G; Ganhão S; Duarte C; Santiago M; Santos MJ
Acta Reumatol Port; 2019; 44(4):266-272. PubMed ID: 32008032
[TBL] [Abstract][Full Text] [Related]
22. Pregnancy outcomes in women exposed to cancer chemotherapy.
Danet C; Araujo M; Bos-Thompson MA; Portolan G; Gautier S; Vanlemmens L; Bonenfant S; Jonville-Béra AP; Cottin J; Vial T; Bavoux F; Montastruc JL; Damase-Michel C; Benevent J; Bourgeois-Mondon I; Lacroix I
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1302-1308. PubMed ID: 30379378
[TBL] [Abstract][Full Text] [Related]
23. Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M; Dogan S
Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
[TBL] [Abstract][Full Text] [Related]
24. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
25. Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study.
Chambers CD; Johnson DL; Xu R; Luo Y; Lopez-Jimenez J; Adam MP; Braddock SR; Robinson LK; Vaux K; Lyons Jones K;
PLoS One; 2019; 14(10):e0223603. PubMed ID: 31626646
[TBL] [Abstract][Full Text] [Related]
26. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
[TBL] [Abstract][Full Text] [Related]
27. Use of colchicine in pregnancy: a systematic review and meta-analysis.
Indraratna PL; Virk S; Gurram D; Day RO
Rheumatology (Oxford); 2018 Feb; 57(2):382-387. PubMed ID: 29029311
[TBL] [Abstract][Full Text] [Related]
28. Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data.
Lau CS; Chen YH; Lim K; de Longueville M; Arendt C; Winthrop K
Clin Rheumatol; 2021 Mar; 40(3):867-875. PubMed ID: 32740672
[TBL] [Abstract][Full Text] [Related]
29. Pregnancy outcomes after maternal exposure to rituximab.
Chakravarty EF; Murray ER; Kelman A; Farmer P
Blood; 2011 Feb; 117(5):1499-506. PubMed ID: 21098742
[TBL] [Abstract][Full Text] [Related]
30. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
31. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.
Weber-Schoendorfer C; Oppermann M; Wacker E; Bernard N; ; Beghin D; Cuppers-Maarschalkerweerd B; Richardson JL; Rothuizen LE; Pistelli A; Malm H; Eleftheriou G; Kennedy D; Kadioglu Duman M; Meister R; Schaefer C
Br J Clin Pharmacol; 2015 Oct; 80(4):727-39. PubMed ID: 25808588
[TBL] [Abstract][Full Text] [Related]
32. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.
McKenna K; Koren G; Tetelbaum M; Wilton L; Shakir S; Diav-Citrin O; Levinson A; Zipursky RB; Einarson A
J Clin Psychiatry; 2005 Apr; 66(4):444-9; quiz 546. PubMed ID: 15816786
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.
Moon W; Pestana L; Becker B; Loftus EV; Hanson KA; Bruining DH; Tremaine WJ; Kane SV
Aliment Pharmacol Ther; 2015 Aug; 42(4):428-40. PubMed ID: 26081839
[TBL] [Abstract][Full Text] [Related]
34. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
35. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
Curtis JR; Winthrop K; O'Brien C; Ndlovu MN; de Longueville M; Haraoui B
Arthritis Res Ther; 2017 Dec; 19(1):276. PubMed ID: 29246162
[TBL] [Abstract][Full Text] [Related]
36. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.
Andreoli L; Gerardi MC; Gerosa M; Rozza D; Crisafulli F; Erra R; Lini D; Trespidi L; Padovan M; Ruffilli F; Serale F; Cuomo G; Raffeiner B; Semeraro P; Tani C; Chimenti MS; Conigliaro P; Hoxha A; Nalli C; Fredi M; Lazzaroni MG; Filippini M; Taglietti M; Franceschini F; Zatti S; Loardi C; Orabona R; Ramazzotto F; Zanardini C; Fontana G; Gozzoli G; Barison C; Bizioli P; Caporali RF; Carrea G; Ossola MW; Maranini B; Silvagni E; Govoni M; Morano D; Verteramo R; Doria A; Del Ross T; Favaro M; Calligaro A; Tonello M; Larosa M; Zen M; Zambon A; Mosca M; Zucchi D; Elefante E; Gori S; Iannone F; Anelli MG; Lavista M; Abbruzzese A; Fasano CG; D'Angelo S; Cutro MS; Picerno V; Carbone T; Padula AA; Rovere-Querini P; Canti V; De Lorenzo R; Cavallo L; Ramoni V; Montecucco C; Codullo V; Milanesi A; Pazzola G; Comitini G; Marvisi C; Salvarani C; Epis OM; Benedetti S; Di Raimondo G; Gagliardi C; Lomater C; Crepaldi G; Bellis E; Bellisai F; Garcia Gonzalez E; Pata AP; Zerbinati M; Urban ML; Mattioli I; Iuliano A; Sebastiani G; Brucato AL; Bizzi E; Cutolo M; Santo L; Tonetta S; Landolfi G; Carrara G; Bortoluzzi A; Scirè CA; Tincani A;
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663885
[TBL] [Abstract][Full Text] [Related]
37. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
38. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
Diav-Citrin O; Shechtman S; Ornoy S; Arnon J; Schaefer C; Garbis H; Clementi M; Ornoy A
J Clin Psychiatry; 2005 Mar; 66(3):317-22. PubMed ID: 15766297
[TBL] [Abstract][Full Text] [Related]
39. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.
Shihab Z; Yeomans ND; De Cruz P
J Crohns Colitis; 2016 Aug; 10(8):979-88. PubMed ID: 26755733
[TBL] [Abstract][Full Text] [Related]
40. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
Pollack PS; Shields KE; Burnett DM; Osborne MJ; Cunningham ML; Stepanavage ME
Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):888-96. PubMed ID: 16163683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
